Cargando…

Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort

BACKGROUND: There are limited data on mobile health detection of prevalent atrial fibrillation (AF) and its related risk factors over time. OBJECTIVES: This study aimed to report the trends on prevalent AF detection over time and risk factors, with a consumer-led photoplethysmography screening appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yutao, Zhang, Hui, Lip, Gregory Y.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700030/
https://www.ncbi.nlm.nih.gov/pubmed/36444321
http://dx.doi.org/10.1016/j.jacasi.2022.07.006
_version_ 1784839216710025216
author Guo, Yutao
Zhang, Hui
Lip, Gregory Y.H.
author_facet Guo, Yutao
Zhang, Hui
Lip, Gregory Y.H.
author_sort Guo, Yutao
collection PubMed
description BACKGROUND: There are limited data on mobile health detection of prevalent atrial fibrillation (AF) and its related risk factors over time. OBJECTIVES: This study aimed to report the trends on prevalent AF detection over time and risk factors, with a consumer-led photoplethysmography screening approach. METHODS: 3,499,461 subjects aged over 18 years, who use smart devices (Huawei Technologies Co.) were enrolled between October 26, 2018, and December 1, 2021. RESULTS: Among 2,852,217 subjects for AF screening, 12,244 subjects (0.43%; 83.2% male, mean age 57 ± 15 years) detected AF episodes. When compared with 2018, the risk (adjusted HRs, 95% CI) for monitored prevalent AF increased significantly for subjects when monitoring started in 2020 (adjusted HR: 1.34; 95% CI: 1.27-1.40; P < .001) or in 2021 (adjusted HR: 1.67; 95% CI: 1.59-1.76; P < 0.001). Of the 961,931 subjects who screening for both AF and OSA, 18,032 (1.9%, 97.8% male, mean age 44 ±17 years) were identified as high risk for OSA, which resulted in a 1.5-fold increase (95% CI: 1.30-fold to 1.75-fold) in the prevalent AF. A total of 5,227 (53.3%, 5,227/9,797) subjects were effectively followed up, from which 4,903 (93.8%, 4,903/5,227) subjects were confirmed with the diagnosis of AF, by the mAFA Telecare Team health providers. CONCLUSIONS: Photoplethysmography-based smart devices can facilitate screening for AF with >93% confirmation of detected AF episodes even for the low-risk general population, highlighting the increased risk for detecting prevalent AF and the need for modification of OSA that increase AF susceptibility. (Mobile Health [mHealth] Technology for Improved Screening, Patient Involvement and Optimizing Integrated Care in Atrial Fibrillation [mAFA (mAF-App) II study]; ChiCTR-OOC-17014138)
format Online
Article
Text
id pubmed-9700030
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97000302022-11-27 Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort Guo, Yutao Zhang, Hui Lip, Gregory Y.H. JACC Asia Original Research BACKGROUND: There are limited data on mobile health detection of prevalent atrial fibrillation (AF) and its related risk factors over time. OBJECTIVES: This study aimed to report the trends on prevalent AF detection over time and risk factors, with a consumer-led photoplethysmography screening approach. METHODS: 3,499,461 subjects aged over 18 years, who use smart devices (Huawei Technologies Co.) were enrolled between October 26, 2018, and December 1, 2021. RESULTS: Among 2,852,217 subjects for AF screening, 12,244 subjects (0.43%; 83.2% male, mean age 57 ± 15 years) detected AF episodes. When compared with 2018, the risk (adjusted HRs, 95% CI) for monitored prevalent AF increased significantly for subjects when monitoring started in 2020 (adjusted HR: 1.34; 95% CI: 1.27-1.40; P < .001) or in 2021 (adjusted HR: 1.67; 95% CI: 1.59-1.76; P < 0.001). Of the 961,931 subjects who screening for both AF and OSA, 18,032 (1.9%, 97.8% male, mean age 44 ±17 years) were identified as high risk for OSA, which resulted in a 1.5-fold increase (95% CI: 1.30-fold to 1.75-fold) in the prevalent AF. A total of 5,227 (53.3%, 5,227/9,797) subjects were effectively followed up, from which 4,903 (93.8%, 4,903/5,227) subjects were confirmed with the diagnosis of AF, by the mAFA Telecare Team health providers. CONCLUSIONS: Photoplethysmography-based smart devices can facilitate screening for AF with >93% confirmation of detected AF episodes even for the low-risk general population, highlighting the increased risk for detecting prevalent AF and the need for modification of OSA that increase AF susceptibility. (Mobile Health [mHealth] Technology for Improved Screening, Patient Involvement and Optimizing Integrated Care in Atrial Fibrillation [mAFA (mAF-App) II study]; ChiCTR-OOC-17014138) Elsevier 2022-11-01 /pmc/articles/PMC9700030/ /pubmed/36444321 http://dx.doi.org/10.1016/j.jacasi.2022.07.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research
Guo, Yutao
Zhang, Hui
Lip, Gregory Y.H.
Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
title Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
title_full Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
title_fullStr Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
title_full_unstemmed Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
title_short Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
title_sort consumer-led screening for atrial fibrillation: a report from the mafa-ii trial long-term extension cohort
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700030/
https://www.ncbi.nlm.nih.gov/pubmed/36444321
http://dx.doi.org/10.1016/j.jacasi.2022.07.006
work_keys_str_mv AT guoyutao consumerledscreeningforatrialfibrillationareportfromthemafaiitriallongtermextensioncohort
AT zhanghui consumerledscreeningforatrialfibrillationareportfromthemafaiitriallongtermextensioncohort
AT lipgregoryyh consumerledscreeningforatrialfibrillationareportfromthemafaiitriallongtermextensioncohort
AT consumerledscreeningforatrialfibrillationareportfromthemafaiitriallongtermextensioncohort